Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...
IO Biotech's vaccines activate T cells to modify the tumor microenvironment, targeting both cancer and immune-suppressive cells. The T-win technology combines IO102 and IO103, targeting IDO and PD-L1, ...
FDA clearance received to start the pivotal, 500-patient, placebo-controlled Phase 3 “PREVAiLS” study of pridopidine in participants with early, rapidly progressive ALS; US recruitment set to begin ...
Immuneering is developing atebimetinib, a novel MEK inhibitor, in multiple solid tumors, having already produced impressive phase 2a data in pancreatic cancer. IMRX's near-term catalyst is the January ...
Confirmatory Phase 3 Trial Designed to Support Commercialization of Multikine for Head and Neck Cancer Treatment Full enrollment expected by Q2 2026 with plans to seek early approval at that time ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results